PMID- 37306192
OWN - NLM
STAT- MEDLINE
DCOM- 20230901
LR  - 20230902
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 15
DP  - 2023 Aug
TI  - Comparison of efficacy and safety of second- and third-generation TKIs for 
      non-small-cell lung cancer with uncommon EGFR mutations.
PG  - 15903-15911
LID - 10.1002/cam4.6229 [doi]
AB  - BACKGROUND: The efficacy of definite for non-small-cell lung cancer (NSCLC) with 
      uncommon epidermal growth factor receptor (EGFR) mutations has been preliminarily 
      demonstrated. However, there is a paucity of data with which to compare the 
      efficacy and safety of second- and third-generation TKIs in patients with NSCLC 
      carrying uncommon EGFR mutations. METHODS: We compared the efficacy and safety of 
      second- and third-generation TKIs in all NSCLC patients in whom next-generation 
      sequencing confirmed uncommon EGFR mutations, including G719X, S768I, and L861Q. 
      The parameters analyzed included the objective response rate (ORR), disease 
      control rate (DCR), progression-free survival (PFS), and overall survival (OS). 
      The rate of treatment-related adverse events (AEs) reflected the safety of these 
      TKIs. RESULTS: Eighty-four NSCLC patients with uncommon EGFR mutations were 
      enrolled between April 2016 and May 2022 at Zhejiang Cancer Hospital, including 
      63 treated with second-generation TKIs and 21 treated with third-generation TKIs. 
      The ORR for all patients receiving TKIs was 47.6%, and the DCR was 86.9%. The 
      median PFS for NSCLC patients with uncommon EGFR mutations receiving TKIs was 
      11.9 months and OS was 30.6 months. There was no significant difference in PFS 
      after treatment with second- or third-generation TKIs (13.3 vs. 11.0 months, 
      respectively, P = 0.910) or in OS (30.6 vs. 24.6 months, respectively P = 0.623). 
      The third-generation TKIs showed no severe toxicity. CONCLUSIONS: The efficacy of 
      second- and third-generation TKIs for NSCLC with uncommon EGFR mutations does not 
      differ, and so can be used to treat NSCLC patients with these mutations.
CI  - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Hao, Yue
AU  - Hao Y
AUID- ORCID: 0000-0002-4725-6084
AD  - The Second Clinical Medical College of Zhejiang Chinese Medical University, 
      Hangzhou, China.
AD  - Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, China.
FAU - Xu, Manyi
AU  - Xu M
AUID- ORCID: 0000-0002-6937-3652
AD  - The Second Clinical Medical College of Zhejiang Chinese Medical University, 
      Hangzhou, China.
AD  - Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, China.
FAU - Jin, Jianan
AU  - Jin J
AD  - Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, China.
FAU - Si, Jinfei
AU  - Si J
AD  - The Second Clinical Medical College of Zhejiang Chinese Medical University, 
      Hangzhou, China.
AD  - Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, China.
FAU - Xu, Chunwei
AU  - Xu C
AUID- ORCID: 0000-0002-9021-6731
AD  - Department of Respiratory Medicine, Jinling Hospital, Nanjing University School 
      of Medicine, Nanjing, China.
FAU - Song, Zhengbo
AU  - Song Z
AD  - Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230612
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (EGFR protein, human)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics
MH  - *Lung Neoplasms/drug therapy/genetics
MH  - Protein Kinase Inhibitors/adverse effects
MH  - Treatment Outcome
MH  - ErbB Receptors/genetics
MH  - Mutation
PMC - PMC10469645
OTO - NOTNLM
OT  - NSCLC
OT  - afatinib
OT  - efficacy
OT  - osimertinib
OT  - safety
OT  - uncommon EGFR mutation
COIS- All authors declare no conflict of interest.
EDAT- 2023/06/12 13:07
MHDA- 2023/09/01 06:43
PMCR- 2023/06/12
CRDT- 2023/06/12 06:44
PHST- 2023/05/26 00:00 [revised]
PHST- 2023/01/22 00:00 [received]
PHST- 2023/06/01 00:00 [accepted]
PHST- 2023/09/01 06:43 [medline]
PHST- 2023/06/12 13:07 [pubmed]
PHST- 2023/06/12 06:44 [entrez]
PHST- 2023/06/12 00:00 [pmc-release]
AID - CAM46229 [pii]
AID - 10.1002/cam4.6229 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Aug;12(15):15903-15911. doi: 10.1002/cam4.6229. Epub 2023 Jun 
      12.